TY - JOUR
T1 - Lack of PPCA expression only partially coincides with lysosomal storage in galactosialidosis mice
T2 - Indirect evidence for spatial requirement of the catalytic rather than the protective function of PPCA
AU - Rottier, Robbert J.
AU - Hahn, Christopher N.
AU - Mann, Linda W.
AU - Del Pilar Martin, Maria
AU - Smeyne, Richard J.
AU - Suzuki, Kinuko
AU - D'Azzo, Alessandra
N1 - © 1998 Oxford University Press
PY - 1998/10/1
Y1 - 1998/10/1
N2 - Protective protein/cathepsin A (PPCA) is a pleiotropic lysosomal enzyme that complexes with β-galactosidase and neuraminidase, and possesses serine carboxypeptidase activity. Its deficiency in man results in the neurodegenerative lysosomal storage disorder galactosialidosis (GS). The mouse model of this disease resembles the human early onset phenotype and results in severe nephropathy and ataxia. To understand better the pathophysiology of the disease, we compared the occurrence of lysosomal PPCA mRNA and protein in normal adult mouse tissues with the incidence of lysosomal storage in PPCA(-/-) mice. PPCA expression was markedly variable among different tissues. Most sites that produced both mRNA and protein at high levels in normal mice showed extensive and overt storage in the knockout mice. However, this correlation was not consistent as some cells that normally expressed high levels of PPCA were unaffected in their storage capability in the PPCA(-/-) mice. In addition, some normally low expressing cells accumulated large amounts of undegraded products in the GS mouse. This apparent discrepancy may reflect a requirement for the catalytic rather than the protective function of PPCA and/or the presence of cell-specific substrates in certain cell types. A detailed map showing the cellular distribution of PPCA in nomal mouse tissues as well as the sites of lysosomal storage in deficient mice is critical for accurate assessment of the effects of therapeutic interventions.
AB - Protective protein/cathepsin A (PPCA) is a pleiotropic lysosomal enzyme that complexes with β-galactosidase and neuraminidase, and possesses serine carboxypeptidase activity. Its deficiency in man results in the neurodegenerative lysosomal storage disorder galactosialidosis (GS). The mouse model of this disease resembles the human early onset phenotype and results in severe nephropathy and ataxia. To understand better the pathophysiology of the disease, we compared the occurrence of lysosomal PPCA mRNA and protein in normal adult mouse tissues with the incidence of lysosomal storage in PPCA(-/-) mice. PPCA expression was markedly variable among different tissues. Most sites that produced both mRNA and protein at high levels in normal mice showed extensive and overt storage in the knockout mice. However, this correlation was not consistent as some cells that normally expressed high levels of PPCA were unaffected in their storage capability in the PPCA(-/-) mice. In addition, some normally low expressing cells accumulated large amounts of undegraded products in the GS mouse. This apparent discrepancy may reflect a requirement for the catalytic rather than the protective function of PPCA and/or the presence of cell-specific substrates in certain cell types. A detailed map showing the cellular distribution of PPCA in nomal mouse tissues as well as the sites of lysosomal storage in deficient mice is critical for accurate assessment of the effects of therapeutic interventions.
UR - http://www.scopus.com/inward/record.url?scp=0031685250&partnerID=8YFLogxK
U2 - 10.1093/hmg/7.11.1787
DO - 10.1093/hmg/7.11.1787
M3 - Article
C2 - 9736781
AN - SCOPUS:0031685250
SN - 0964-6906
VL - 7
SP - 1787
EP - 1794
JO - Human Molecular Genetics
JF - Human Molecular Genetics
IS - 11
ER -